Ekspresja receptora Sigma-1 w przewlekłych modelach zwierzęcych epilepsji płata skroniowego

PubMed➕ 26.08.2026Mol Neurobiol

Sigma-1 Expression in Chronic Mouse Models of Temporal Lobe Epilepsy

W skrócie

Badacze sprawdzili, jak zmienia się białko Sigma-1 w mózgach myszy z epilepsją płata skroniowego na różnych etapach choroby. Białko Sigma-1 pozostawało w mózgu względnie stabilne, ze znaczącym wzrostem tylko krótko po ataku padaczkowym, co sugeruje, że może być dobrym celem do leczenia epilepsji. Wyniki wskazują, że Sigma-1 warto rozważać jako potencjalny lek, szczególnie jeśli podawać go wcześnie, zanim epilepsja się w pełni rozwinie.

Oryginalny abstract (angielski)

Sigma-1 is an atypical receptor protein that modulates neuronal excitability and cellular stress responses, making it a promising target for therapeutic epilepsy management. However, its expression profile following epileptogenic insults, during epileptogenesis, and following chronic epilepsy manifestation remains unclear. We investigated brain Sigma-1 expression immunohistochemically and via quantitative PCR in two chronic mouse models of temporal lobe epilepsy: the amygdala kindling and intrahippocampal kainate model. Thereby, different disease phases were considered from the early phase following an epileptogenic insult, epileptogenesis, to the chronic epileptic state with recurrent seizures. Sigma-1 expression was largely stable across the examined brain areas. Transient increases in expression intensity were observed 2 days after status epilepticus in the kainate model in the CA3 region of the hippocampus and the entorhinal cortex, whereas no persistent protein-level reductions were detected in the chronic phase. Descriptive coexpression analyses indicated Sigma-1 expression in excitatory and inhibitory neurons, astrocytes, and microglia. These findings indicate that Sigma-1 expression is preserved during epileptogenesis and chronic epilepsy, supporting the continued consideration of Sigma-1 as a potential therapeutic target in epilepsy management. The early alterations observed following an epileptogenic insult further support the rationale for investigating Sigma-1-directed interventions during epileptogenesis, including preventive antiepileptogenic approaches.

Metadane publikacji

Journal
Mol Neurobiol
Data publikacji
25.08.2026
PMID
42642676
DOI
10.1007/s12035-026-06155-6
Autorzy
Stocker VM, Lad C, Markov A, Potschka H, von Rüden EL
Słowa kluczowe
Amygdala kindling model, Antiseizure medication, Immunohistochemistry, Intrahippocampal kainate model, Target validation, Temporal lobe epilepsy
Źródło
PubMed